Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern

Documenti analoghi

• Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real‐World Data
  di: David C. Sealey, et al.
  Pubblicazione: (2025)
• Point‐of‐Care Intestinal Ultrasound Impacts Inflammatory Bowel Disease Care and Reduces the Need for Additional Investigations
  di: Wei‐Lian Tan, et al.
  Pubblicazione: (2025)
• A Critical Review of Persistent Gastrointestinal and Extraintestinal Symptoms in Quiescent Inflammatory Bowel Disease: Time for Greater Precision and Clarity
  di: Alexandra Mack, et al.
  Pubblicazione: (2026)
• Role of the Dietitian in the Inflammatory Bowel Disease Multidisciplinary Team
  di: Nicky E. McCarthy, et al.
  Pubblicazione: (2025)
• The Emerging Role of CCL17 in the Immunologic Regulation of Inflammatory Bowel Disease
  di: Cong Zhang, et al.
  Pubblicazione: (2025)